Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q71RH2

UPID:
TLC3B_HUMAN

ALTERNATIVE NAMES:
Protein FAM57B; TLC domain-containing protein 3B

ALTERNATIVE UPACC:
Q71RH2; Q9H0J1

BACKGROUND:
The protein Ceramide synthase, known alternatively as Protein FAM57B or TLC domain-containing protein 3B, is integral to the synthesis of ceramides. These lipids are pivotal for cell membrane integrity and signaling pathways. The protein's diverse nomenclature reflects its critical function in lipid metabolism.

THERAPEUTIC SIGNIFICANCE:
Given its association with Cone-rod dystrophy 22, a condition marked by early vision loss, Ceramide synthase represents a promising target for drug discovery. Exploring the protein's role could lead to innovative treatments for retinal dystrophies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.